225 related articles for article (PubMed ID: 30768848)
21. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
22. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
23. Role of Lin28A/let-7a/c-Myc Pathway in Growth and Malignant Behavior of Papillary Thyroid Carcinoma.
Huang J; Lin H; Zhong M; Huang J; Sun S; Lin L; Chen Y
Med Sci Monit; 2018 Dec; 24():8899-8909. PubMed ID: 30531691
[TBL] [Abstract][Full Text] [Related]
24. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma.
Sisdelli L; Cordioli MICV; Vaisman F; Moraes L; Colozza-Gama GA; Alves PAG; Araújo ML; Alves MTS; Monte O; Longui CA; Cury AN; Carvalheira G; Cerutti JM
Pediatr Blood Cancer; 2019 Jul; 66(7):e27707. PubMed ID: 30924609
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
26. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
27. Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF
Li L; Li H; Zhang J; Gao X; Jin H; Liu R; Zhang Z; Zhang X; Wang X; Qu P; Zhao Y; Lu X
J Cell Mol Med; 2021 Feb; 25(3):1739-1749. PubMed ID: 33469997
[TBL] [Abstract][Full Text] [Related]
28. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
29. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
[No Abstract] [Full Text] [Related]
30. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
[TBL] [Abstract][Full Text] [Related]
31. BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers.
Gao Y; Zhang D; Wang F; Zhang D; Li P; Wang K
J Cell Mol Med; 2022 Jul; 26(14):4048-4060. PubMed ID: 35748101
[TBL] [Abstract][Full Text] [Related]
32. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.
Jing FJ; Liang J; Liang ZY; Meng C; Long W; Li XY; Lin YS
Chin Med J (Engl); 2013 Aug; 126(16):3013-8. PubMed ID: 23981603
[TBL] [Abstract][Full Text] [Related]
33. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.
Wang F; Zhao S; Shen X; Zhu G; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Wang Y; Xing M
J Clin Oncol; 2018 Sep; 36(27):2787-2795. PubMed ID: 30070937
[TBL] [Abstract][Full Text] [Related]
35. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
36. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
37. Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.
Xu X; Ma X; Zhang X; Cao G; Tang Y; Deng X; Kang Z; Li M; Guan M
Clin Chim Acta; 2019 Apr; 491():91-96. PubMed ID: 30682328
[TBL] [Abstract][Full Text] [Related]
38. Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.
Kim BA; Jee HG; Yi JW; Kim SJ; Chai YJ; Choi JY; Lee KE
Cancer Genomics Proteomics; 2017 Jan; 14(1):53-67. PubMed ID: 28031237
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
Abd Elmageed ZY; Sholl AB; Tsumagari K; Al-Qurayshi Z; Basolo F; Moroz K; Boulares AH; Friedlander P; Miccoli P; Kandil E
Surgery; 2017 Apr; 161(4):1122-1128. PubMed ID: 27919446
[TBL] [Abstract][Full Text] [Related]
40. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Exp Mol Pathol; 2015 Dec; 99(3):492-7. PubMed ID: 26403329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
